-
Women's Heavy Blend Zip Hoodie (Embroidered Purple Ribbon)
Regular price From $46.50 USDRegular priceUnit price per -
Women's Lightweight Zip Hoodie (Embroidered Purple Ribbon)
Regular price From $54.00 USDRegular priceUnit price per -
Women's Lightweight Zip Hoodie (Embroidered Sky Logo)
Regular price From $54.50 USDRegular priceUnit price per -
Women's Quarter Zip (Embroidered Purple Ribbon)
Regular price From $62.00 USDRegular priceUnit price per -
Women's Quarter Zip (Embroidered SKY Logo)
Regular price From $62.00 USDRegular priceUnit price per -
Women's Relaxed T-Shirt
Regular price From $37.00 USDRegular priceUnit price per -
Women's V-Neck Tee (Purple Ribbon)
Regular price $26.70 USDRegular priceUnit price per -
Women's V-Neck Tee (Supporter Jersey)
Regular price $26.70 USDRegular priceUnit price per -
Women's V-Neck Tee (Survivor Jersey)
Regular price $26.70 USDRegular priceUnit price per -
Women's Wind Breaker Jacket (Embroidered Purple Ribbon)
Regular price From $64.00 USDRegular priceUnit price per -
Women’s Columbia Fleece Vest
Regular price From $64.00 USDRegular priceUnit price per -
Women’s Relaxed V-Neck Tee (Embroidered Purple Ribbon)
Regular price From $40.00 USDRegular priceUnit price per -
Women’s Tank Top
Regular price $29.00 USDRegular priceUnit price per
Latest News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
